# CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

> **NCT03727789** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- Advanced Cutaneous Melanoma of the Extremity
- Advanced Sarcoma of the Extremity
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Recurrent Cutaneous Melanoma of the Extremity
- Recurrent Sarcoma of the Extremity
- Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

## Interventions

- **DRUG:** FACT Complex-targeting Curaxin CBL0137

## Key facts

- **NCT ID:** NCT03727789
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-01
- **Primary completion:** 2024-01-16
- **Final completion:** 2024-01-16
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2024-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03727789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03727789, "CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03727789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*